Anadys
Anadys Pharmaceuticals, a biopharmaceutical company, develops medicines for the treatment of hepatitis C.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Anadys Information
Geographic Data
Address:
City: San Diego
State: California
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$18M
Raised Total:$18M
Social
Metrics
1,227,823Website Global Rank
20,997Website Monthly Traffic
Twitter Followers
Description
Anadys Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines for the treatment of hepatitis C. The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
Contact Phone:
Contact Email:
Anadys went public on 3/26/2004 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
3/26/2004
Ticker Symbol:
ANDS
IPO Price:
$7/share
Amount Raised:
$44M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2009 | Post-IPO Equity | $17.5M |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
